AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

AbbVie Inc.NYSE: ABBV

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation dips below year-ago levels

Q2 FY2026 stock-based compensation of $166M fell 7.3% year over year, behind the +4.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 62.6% from the prior quarter. Over 3 fiscal years it compounded at +12.5% a year.

Context

  • Stock-based compensation amounted to 1.6% of revenue in FY2025, unchanged from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -7.3% toward the trailing-twelve-month pace of +4.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$166M-62.6% QoQ
Last fiscal yearDec 2025
$955M+4.8% YoY
LTMJun 2026
$976M+4.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.3%——
1 year+4.8%——
3-year CAGR+12.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
955M USD
Year-over-year change
+4.8%
4-year CAGR
+8.4%

Stock-Based Compensation vs competitors

How ABBV compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.5% is the 5th highest of 8, against a peer median of +5.8%.
  • Stock-based compensation amounts to 1.5% of revenue for ABBV, versus a peer median of 1.1%.
ABBV Competitors
Stock-Based Compensation for ABBV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$1.42B USD+11.0%+6.0%1.4%
ABBVAbbVie Inc.LTM Jun 2026$976M USD+4.5%+12.5%1.5%
PFEPfizer Inc.LTM Jun 2026$947M USD+14.9%-2.9%1.5%
MRKMerck & Co., Inc.LTM Jun 2026$892M USD+12.5%—1.3%
LLYEli Lilly and CompanyLTM Jun 2026$649.2M USD+5.8%+19.0%0.8%
NVSNovartis AGLTM Jun 2026$571M USD-45.9%—1.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$553M USD+4.3%+6.6%1.1%
AMGNAmgen Inc.LTM Jun 2026$492M USD-3.9%+7.2%1.3%
AZNAstraZeneca PLCLTM Sep 2026$0 USD——0.0%
GSKGSK plcLTM Jun 2026£0 GBP——0.0%
Peer median (excluding ABBV) —+5.8%+6.6%1.1%

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income11.55B11.85B4.82B4.29B4.23B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
Deferred Income Tax(898M)(1.93B)(2.89B)(1.45B)(492M)
Stock-Based Compensation692M671M747M911M955M
Change in Working Capital(1.32B)(258M)2.81B(2.78B)(2.36B)
Accounts Receivables(1.32B)(1.46B)66M207M(1.49B)
Inventory(142M)(686M)(417M)(319M)(234M)
Accounts Payables1.63B1.61B3.84B177M951M
Other Working Capital(1.49B)278M(676M)(2.85B)(1.59B)
Other Non-Cash Items4.24B6.15B8.65B9.45B8.6B
Operating Cash Flow22.78B24.94B22.84B18.81B19.03B
Capital Expenditures(787M)(695M)(777M)(974M)(1.21B)
Acquisitions (Net)(1.9B)(794M)(1.22B)(17.49B)(204M)
Purchases of Investments(119M)(1.44B)(77M)(73M)(35M)
Sales of Investments98M1.53B55M555M76M
Other Investing Activities366M774M13M(2.84B)(5.27B)
Investing Cash Flow(2.34B)(623M)(2.01B)(20.82B)(6.64B)
Debt Repayment(8.41B)(12.43B)(4.15B)7.35B(327M)
Common Stock Issued0000172M
Common Stock Repurchased(934M)(1.49B)(1.97B)(1.71B)(980M)
Dividends Paid(9.26B)(10.04B)(10.54B)(11.03B)(11.66B)
Other Financing Activities(430M)(840M)(562M)172M68M
Financing Cash Flow(19.04B)(24.8B)(17.22B)(5.21B)(12.72B)
Effect of Forex Changes(97M)(62M)5M(65M)42M
Net Change in Cash1.3B(545M)3.61B(7.29B)(295M)
Free Cash Flow21.99B24.25B22.06B17.83B17.82B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.